NEVVI Medicare utilization intelligence

← back

KURKUL, CHARLESM.D. NPI 1134419682 Clinician

Medical Oncology · DENTON, TX

Specialty Medical Oncology — from billed Medicare claims
Trained UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL — medical school, self-reported to CMS
In practice about 15 years since medical school (class of 2011, self-reported to CMS)
Location DENTON, TX · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 70 codes billed · 114,037 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
TEXAS ONCOLOGY PA
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2023-01

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1453 Injection, fosaprepitant, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J9271 Injection, pembrolizumab, 1 mg
J1756 Injection, iron sucrose, 1 mg
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J0461 Injection, atropine sulfate, 0.01 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
J0640 Injection, leucovorin calcium, per 50 mg
J2469 Injection, palonosetron hcl, 25 mcg
80053 Blood test, comprehensive group of blood chemicals
83615 Lactate dehydrogenase (enzyme) level
J9190 Injection, fluorouracil, 500 mg
36415 Insertion of needle into vein for collection of blood sample
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J9206 Injection, irinotecan, 20 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96375 Injection of additional new drug or substance into vein
J1626 Injection, granisetron hydrochloride, 100 mcg
96413 Administration of chemotherapy into vein, 1 hour or less
J9045 Injection, carboplatin, 50 mg
J3475 Injection, magnesium sulfate, per 500 mg
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
82728 Ferritin (blood protein) level
83540 Iron level
83550 Iron binding capacity
J3480 Injection, potassium chloride, per 2 meq
96372 Injection of drug or substance under skin or into muscle
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96415 Administration of chemotherapy into vein, each additional hour
J3489 Injection, zoledronic acid, 1 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
85007 Microscopic examination for white blood cells with manual cell count
85027 Complete blood cell count (red cells, white blood cell, platelets), automated test
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
71260 Ct scan of chest with contrast
83735 Magnesium level
74177 Ct scan of abdomen and pelvis with contrast
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
85055 Reticulated (young) platelet measurement
96411 Administration of additional new drug or substance into vein using push technique
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
J1200 Injection, diphenhydramine hcl, up to 50 mg
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
84550 Uric acid level, blood
96523 Irrigation of implanted venous access drug delivery device
J7030 Infusion, normal saline solution , 1000 cc
96374 Injection of drug or substance into vein
85046 Red blood count automated, with additional calculations
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
85045 Red blood count, automated test
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
J3490 Unclassified drugs
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
G6015 Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96360 Infusion into a vein for hydration, 31-60 minutes
71250 Ct scan of chest without contrast
96361 Infusion into a vein for hydration, each additional hour
74176 Ct scan of abdomen and pelvis without contrast
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.